Viana B, Gomes A, Gimba E, Ferreira L
Biomedicines. 2021; 9(10).
PMID: 34680488
PMC: 8533224.
DOI: 10.3390/biomedicines9101372.
Mokrysheva N, Eremkina A, Mirnaya S, Krupinova J, Voronkova I, Kim I
Probl Endokrinol (Mosk). 2021; 67(4):94-124.
PMID: 34533017
PMC: 9753843.
DOI: 10.14341/probl12801.
Baykan E, Erdogan M
Turk J Med Sci. 2020; 51(2):650-656.
PMID: 33128357
PMC: 8203141.
DOI: 10.3906/sag-2003-182.
Marx S, Goltzman D
J Bone Miner Res. 2018; 34(1):22-37.
PMID: 30536424
PMC: 6396287.
DOI: 10.1002/jbmr.3650.
Khatami F, Tavangar S
Biomark Insights. 2018; 13:1177271918785129.
PMID: 30013307
PMC: 6043927.
DOI: 10.1177/1177271918785129.
2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.
Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams G
Eur Thyroid J. 2014; 1(4):216-31.
PMID: 24783025
PMC: 3821492.
DOI: 10.1159/000346174.
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells Jr S, Pacini F, Robinson B, Santoro M
J Clin Endocrinol Metab. 2013; 98(8):3149-64.
PMID: 23744408
PMC: 5399478.
DOI: 10.1210/jc.2013-1204.
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.
Romei C, Pardi E, Cetani F, Elisei R
J Oncol. 2012; 2012:705036.
PMID: 23209466
PMC: 3503399.
DOI: 10.1155/2012/705036.
Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.
A T, F S, G P, M B
Curr Genomics. 2012; 12(8):618-25.
PMID: 22654561
PMC: 3271314.
DOI: 10.2174/138920211798120835.
Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.
Mian C, Barollo S, Zambonin L, Pennelli G, Bernante P, Pelizzo M
Fam Cancer. 2009; 8(4):379-82.
PMID: 19475497
DOI: 10.1007/s10689-009-9250-z.
Myxedema masking primary hyperparathyroidism.
Peter S, Brignol Y
J Natl Med Assoc. 1993; 85(6):471-2.
PMID: 8366539
PMC: 2571858.
VMA excretion in patients with pheochromocytoma.
Farndon J, DAVIDSON H, Johnston I, Wells Jr S
Ann Surg. 1980; 191(3):259-63.
PMID: 7362291
PMC: 1344693.
DOI: 10.1097/00000658-198003000-00001.
Multiple endocrine neoplasia, type II: a combined surgical and genetic approach to treatment.
Partington M, Ghent W, Sears E, Simpson N
Can Med Assoc J. 1981; 124(4):403-10.
PMID: 7214269
PMC: 1705209.
99mTc-phosphonates for imaging of amyloid in C-cell carcinoma.
Reuter E, Bethge N, Matthes M, Koppenhagen K
Eur J Nucl Med. 1983; 8(9):398-400.
PMID: 6628440
DOI: 10.1007/BF00253215.
Scintigraphic studies in patients with medullary carcinoma of the thyroid.
Rasmusson B
Eur J Nucl Med. 1982; 7(4):150-1.
PMID: 6281017
DOI: 10.1007/BF00443920.
Preliminary report of a kindred affected from MEN IIa.
Libroia A, CREMONCINI C, Valente C, Silvestrini F, Palmieri B, Romani F
J Endocrinol Invest. 1984; 7(5):513-6.
PMID: 6150956
DOI: 10.1007/BF03348459.
Bilateral pheochromocytomas.
Kalff V, Shapiro B, Lloyd R, Nakajo M, Sisson J, BEIERWALTES W
J Endocrinol Invest. 1984; 7(4):387-92.
PMID: 6150055
DOI: 10.1007/BF03351022.
Prevalence of C-cell hyperplasia and medullary thyroid carcinoma in a consecutive series of pheochromocytoma patients.
Jansson S, Hansson G, Salander H, Stenstrom G, Tisell L
World J Surg. 1984; 8(4):493-500.
PMID: 6148808
DOI: 10.1007/BF01654922.
Sipple's syndrome: a case diagnosed preoperatively.
Obara T, Fujimoto Y, Oka A, Fukumitsu M
Jpn J Surg. 1974; 4(3):175-82.
PMID: 4464373
DOI: 10.1007/BF02468623.
Familial neurofibromatosis and hypertrophic cardiomyopathy.
Fitzpatrick A, Emanuel R
Br Heart J. 1988; 60(3):247-51.
PMID: 3140859
PMC: 1216562.
DOI: 10.1136/hrt.60.3.247.
